Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.13 CAD
Change Today +0.005 / 4.17%
Volume 15.0K
DMA On Other Exchanges
As of 9:47 AM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

diamedica inc (DMA) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/11/14 - C$0.80
52 Week Low
12/2/14 - C$0.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DIAMEDICA INC (DMA)

Related News

No related news articles were found.

diamedica inc (DMA) Related Businessweek News

No Related Businessweek News Found

diamedica inc (DMA) Details

DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company’s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

3 Employees
Last Reported Date: 04/30/15
Founded in 2000

diamedica inc (DMA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$276.5K
Vice-President of Research
Total Annual Compensation: C$177.0K
Consulting Chief Medical Officer
Total Annual Compensation: C$11.8K
Compensation as of Fiscal Year 2013.

diamedica inc (DMA) Key Developments

Diamedica Inc. Auditor Raises 'Going Concern' Doubt

Diamedica Inc. filed its Annual on Apr 30, 2015 for the period ending Dec 31, 2014. In this report its auditor, KPMG LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

DiaMedica Corporation Presents at 12th Annual BIO Asia International Conference, Mar-24-2015 04:30 PM

DiaMedica Corporation Presents at 12th Annual BIO Asia International Conference, Mar-24-2015 04:30 PM. Venue: Grand Hyatt Hotel, Tokyo, Japan.

DiaMedica Inc. to Expand Focus of DM199 Development into Acute Vascular Diseases

DiaMedica Inc. announced that the company will pursue the development of DM199, its recombinant form of the naturally occurring protein, tissue kallikrein-1 in acute vascular disease of the brain, kidney and heart. The primary focus will be on acute ischemic stroke and acute kidney injury indications. Stroke represents an area of tremendous unmet medical need. Published pre-clinical and clinical research with a naturally occuring tissue kallikrein-1 has demonstrated reduced blood pressure, cell death, inflammation and increased angiogenesis (creation of new blood vessels). As such DiaMedica's recombinant form of tissue kallikrein-1 has the potential to treat a broad spectrum of clinical scenarios where re-establishing blood flow and reducing inflammation in patients is vital to preserving organ function (e.g. brain, kidney and heart). Lower tissue kallikrein-1 levels in the blood have been independently associated with first-ever stroke and are an independent predictor of recurrence after an initial stroke.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DMA:CN C$0.13 CAD +0.005

DMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DMA.
View Industry Companies

Industry Analysis


Industry Average

Valuation DMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIAMEDICA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at